| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
Clinical Research and Product Registration of Biopharmaceuticals/Vaccines in India and China | |
| |
February 20, 2007 |
|
|
| |
|
|
| |
|
|
|
Drug Information Association, Omni San Diego Hotel, 675 L Street, San Diego, CA, USA
Apr 26 2007
The conference aims to provide a detailed analysis of what it takes to conduct clinical trials from a biopharmaceuticals and vaccines perspective in India and China, to address: risk/benefit balance; anecdotal experiences of the multinational pharmaceutical industry in China and India; selection and role of CROs; logistics of operations; clinical trials management; government policies (including IPR issues); and pharmacovigilance.
Keynote Address:
Why India and China – Emerging Markets in Biopharmaceutical Development
KEY TOPICS
•Why India and China – Emerging Markets in Drug Development and Conducting Clinical Research in India and China: New and Experienced Perspectives.
•Logistics and Operations of Clinical Research in China and India for Biopharmaceuticals
•Strategic Outsourcing and Partnership with China and India – CRO Infrastructure, Analysis and Performance
•Drug Registration of Biopharmaceuticals/Vaccines in China and India – (Process of drug registrations)
•Government Policy and Regulatory Environment
•Trade-related Aspects of Intellectual Property Rights (TRIPS) and Government Policies in Both China and India
•Data Management: China and India
•Early Phase and Phase I Clinical Trial Conduct: China and India.
|
|
|
|
|
|
|
|
Organized by:
|
|
Drug Information Association |
|
|
Invited Speakers:
|
|
Kenneth I. Kaitin, PhD
Director of the Tufts Center for the Study of Drug Development
Associate Professor of Medicine
Tufts University School of Medicine, Tufts University.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
http://www.diahome.org/product/13536/07012.pdf
|
|
|
E-mail:
|
|
dia@diahome.org
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|